Alcohol Use Disorder Clinical Trial
Official title:
CM Treatment for Alcohol Dependence Using New Technology
Verified date | May 2019 |
Source | UConn Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Contingency management (CM) is highly efficacious for reducing substance use, and recent data
suggest that reinforcing attendance at treatment can significantly improve treatment
outcomes. Importantly, CM interventions that reinforce attendance are more likely to be
adopted clinically than those that reinforce abstinence. Having objective indicators of
drinking outcomes, nevertheless, is critical for quantifying the benefits of attendance-based
CM treatment in alcohol abusing populations. New technology is now available to gauge alcohol
use in patients' natural environments. The Secure Continuous Remote Alcohol Monitor (SCRAMx®)
continuously monitors alcohol consumption 24 hours a day. As such, it may be ideal for
objective evaluation of alcohol consumption during treatment intervention studies, including
those that involve CM.
In this study, 114 patients participating in community based outpatient treatment programs
for alcohol use disorders will wear SCRAMx for a 12-week period. They will be randomized to
standard care or standard care plus CM, with reinforcement contingent upon attendance at
treatment. The investigators will assess treatment attendance and alcohol use via SCRAMx and
self reports. The investigators expect that patients randomized to the CM intervention will
remain in treatment longer and show reductions in both SCRAMx assessed and self reported
drinking days relative to those randomized to standard care.
Status | Completed |
Enrollment | 114 |
Est. completion date | March 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - age 18 years or older - current diagnosis of alcohol use disorder - able to pass an informed consent quiz - agree to wear a SCRAMx monitor for 12 weeks - have a standard, SCRAMx compatible phone line in their home or agree to attend the clinic at least every other week for data downloads - agree to sign an off-campus property transfer form and return SCRAMx equipment in 12 weeks Exclusion Criteria: - serious, uncontrolled psychiatric illness - in recovery from pathological gambling - unstable address - intend to participate in activities incompatible with SCRAMx in the next 3 months - are wearing SCRAMx for legal purposes |
Country | Name | City | State |
---|---|---|---|
United States | Regional Network of Programs, Inc. | Bridgeport | Connecticut |
United States | Alcohol and Drug Recovery Centers, Inc. | Hartford | Connecticut |
Lead Sponsor | Collaborator |
---|---|
UConn Health | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | longest duration of actively attending treatment | patient attendance to treatment groups as verified by clinic records (number of days attended out of number of days expected to treatment) | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04788004 -
Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
|
||
Recruiting |
NCT05684094 -
Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function
|
N/A | |
Completed |
NCT03406039 -
Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems
|
N/A | |
Completed |
NCT03573167 -
Mobile Phone-Based Motivational Interviewing in Kenya
|
N/A | |
Completed |
NCT04817410 -
ED Initiated Oral Naltrexone for AUD
|
Phase 1 | |
Active, not recruiting |
NCT04267692 -
Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders
|
N/A | |
Completed |
NCT03872128 -
The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders
|
Phase 1 | |
Completed |
NCT02989662 -
INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers
|
Phase 1/Phase 2 | |
Recruiting |
NCT06030154 -
Amplification of Positivity for Alcohol Use
|
N/A | |
Active, not recruiting |
NCT05419128 -
Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19
|
N/A | |
Completed |
NCT04564807 -
Testing an Online Insomnia Intervention
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04203966 -
Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
|
||
Recruiting |
NCT05861843 -
Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
|
||
Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
Enrolling by invitation |
NCT04128761 -
Decreasing the Temporal Window in Individuals With Alcohol Use Disorder
|
N/A | |
Not yet recruiting |
NCT06337721 -
Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults
|
N/A | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Enrolling by invitation |
NCT02544581 -
Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare
|
N/A |